

## Index

### **a**

AI models of adverse drug reactions 271  
 algin 35  
 alginate 12, 35, 37, 53, 56, 71, 80, 125, 195, 222  
 alginate–chitosan microsphere (ACMS) hydrogels 56  
 alginic acid 35–37  
 amphiphilic molecules 100, 192, 203  
 angiogenesis in self-assembled systems 194–197  
 antibody against epithelial cell adhesion molecule (anti-EpCAM) 224  
 antigen-responsive hydrogel 48, 78–79, 83  
 antisense oligonucleotides 35, 106, 166  
 apoptosis 11, 31, 38, 116–120, 123, 128, 139, 228, 269, 278, 280  
 aptamer responsive-hydrogels 81–82, 84  
 artificial general intelligence 270  
 artificial intelligence (AI) 270–272  
 artificial narrow intelligence (ANI) 270  
 artificial super-intelligence 270  
 atomic force microscopy (AFM) 106, 124–125  
 autophagy 116, 118–120, 128, 278, 280

### **b**

basic fibroblast growth factor (bFGF) 193, 195–198  
 biochip technology 181, 182, 262  
 biodegradable polymers 2, 10, 71, 164–167, 180, 189, 211, 263

biodegradable protein hydrogels 99, 228  
 biodegradable water-soluble polysaccharide–SPM 34  
 biohazards 32, 274–275  
 biomaterials  
 limitations 275–277  
 in medicine 28–29  
 surface properties 6  
 technology 1  
 biomedical engineering  
 applications  
 consumer goods 12  
 medicine 12  
 pharmaceutical 11  
 frontiers 1–9  
 impact  
 early stage detection 10–11  
 personalized medicine 11  
 target drug delivery 10  
 materials 9, 23–30, 182, 183, 264  
 bone Gla protein 198  
 bone morphogenetic proteins (BMPs) 197  
 bone regeneration 37, 197–198  
 bottom-up approach 9, 96, 183, 264, 274  
 brittle fracture 5

### **c**

carbon dots (CDs) 120, 220–221  
 carbon nanomaterials 219–220  
 carbon nanotubes (CNT) 219

- cardiac regeneration 199–200
  - cartilage regeneration and
    - biomineralization 193–194
  - cationic antimicrobial peptides 101
  - cationic polysaccharides 31, 34
  - cell cytotoxicity assays 128–129
  - cell death mechanisms 116, 118–121, 128
  - cell therapy 7, 13, 200
  - cell viability 33, 53, 127, 129, 130, 224, 269, 280
  - cell viability assay 127–128
  - chitosan 12, 29–33, 37, 55–58, 68, 70, 71, 80, 142, 166, 213, 215, 222
  - chondroitin sulfate 37, 38, 72, 122, 269
  - clinically-approved biomaterials 277–281
  - cochlear implant 4, 267
  - comb-type hydrogel 59
  - con A hydrogels 56–58
  - confocal laser scanning microscopy (CLSM) 125–126
  - conventional 2D technology 255
  - cross-linked carboxymethyl dextran (CM-dex)-Con A hydrogel membranes 57
  - curcumin 105, 106, 125
  - cyclodextrins (CD) 31, 33
  - cytotoxicity 32, 35, 37, 39, 53, 68, 71, 107, 115–144, 169, 211, 219, 226, 275, 278, 280
- d**
- dark-field microscopy 126
  - degradable hydrogels 71, 72, 76
  - dendrimers 10, 131, 139, 166, 211–213, 216
  - deoxyribonucleic acid (DNA) 48
  - dextran 9, 31, 33–35, 39, 55, 57, 71–73, 134, 166, 213, 215
  - dextran–spermine (D-SPM) 33–36, 39, 40
  - DNA-responsive hydrogels 80–81, 84
  - document processing 272
  - drug delivery system
    - chemical mechanisms 3
    - physical mechanisms 3
  - drug delivery technology
    - biodegradable polymers 164–167
    - MRI technology 169
    - target drug delivery 167–168
    - ultrasound technology 169–170
  - ductile fracture 5
- e**
- electronic biomaterials 4
  - electrospinning 24, 96, 180, 191, 192, 221, 222
  - environmental, health, and safety issues 273–274
  - enzyme-mediated disassembly 75–77
  - enzyme-responsive hydrogels 48
    - degradable hydrogels 71
    - formation of 69–71
    - hydrogel swelling 73
  - enzyme self-assembly 73–75
  - extracellular matrix (ECM) 7, 30, 95, 168, 175, 192, 194, 199, 211, 221, 222, 268, 269
- f**
- fatigue fracture 6
  - 5-fluorouracil (5-FU) 105
- g**
- gas foaming 177, 190, 260, 261
  - gelatin 9, 29–31, 69–71, 195, 212, 222, 226
  - gene delivery 1, 10, 11, 31–34, 37–39, 80, 83, 107, 140, 163–166, 171, 212–216, 222, 223, 277
  - gene silencing 32, 166, 167
  - gene therapy 11, 32, 34, 96, 106, 140, 163, 164, 170, 214, 274, 276
  - gene transfection 32, 37, 39, 163–165, 168, 169, 214
  - genotoxicity 116, 121–122, 129, 275, 279
  - glucose oxidase (GOx) hydrogels 54–56
  - glucose-responsive hydrogels 47

con A hydrogels 56–58  
 glucose oxidase (GOx) hydrogels  
 54–56  
 phenylboronic acid hydrogels 58–59  
 glutaredoxin (Grx) enzymes 117  
 glycosaminoglycans 37–40, 194  
 gold nanoclusters (AuNCs) 210  
 gold nanoparticles 81, 99, 215–217  
 graphene 211, 219, 279

## **h**

hardness testing 5  
 heparin 37, 38, 195  
 high-throughput screening (HTS) 26,  
 122, 178, 262–263  
 hyaluronic acid (HA) 12, 26, 37, 71, 222  
 hydrogel–protein bioconjugates 28  
 hydrogel shrinking 60–63  
 hydrogel swelling 55, 59–61, 73, 78, 81,  
 82  
 hydrophilic polymers 25, 39, 47, 215,  
 219  
 hydroxyethyl starch 38  
 hydroxypropyl cellulose 37, 65

## **i**

immune response 48, 78, 118, 122–123,  
 139, 165, 214, 279  
 impact tests 5  
 information engines 271  
 injectable hydrogel 70, 72, 80, 197  
 inorganic NPs 210, 281  
*in silico* assay 130  
 intelligent biomaterials 268–269  
 interpenetrating networks (IPNs) 49, 50  
 interpenetrating polymer networks (IPNs)  
 49  
*in vitro* cell-based cytotoxicity assay 127  
*in vivo* metabolism of NPs 134  
 iron oxide nanoparticles (IONPs) 9, 214,  
 215

## **l**

light-scattering microscopy 126–127  
 lipid NPs (LNPs) 136, 137, 213–214

lipopeptides 101, 102, 104, 108  
 lithography 10, 81, 178–181, 223, 262

## **m**

magnetic NPs 125, 167, 214–215  
 mass loss 24  
 mechanism of toxicity  
 cell death mechanisms 118–121  
 genotoxicity 121–122  
 immune response 122–123  
 oxidative stress 116–118  
 mesenchymal stem cells (MSCs) 28, 72,  
 103, 188  
 mesoporous silica NPs (MSNPs) 131,  
 140, 210–211, 217, 218  
 micelles 10, 98, 102, 104–108, 126,  
 138–140, 143, 166, 167, 203,  
 211–213, 217, 219, 227, 276, 278,  
 279, 281  
 microelectromechanical systems (MEMS)  
 178  
 microfluidic channels 26, 181, 262  
 microgels 28, 58, 63–67  
 micromolding techniques 181, 262  
 micropatterning techniques 11  
 microscale technologies 10, 178, 179  
 molecular nanotechnology 96, 115, 209  
 molecular switch peptides 99, 228  
 MRI technology 169  
 multilayer hydrogel films 67–68  
 multiwalled nanotubes (MWNTs) 219

## **n**

nanodiamonds (NDs) 211, 221  
 nanofabrication 178–181  
 nanofibers 24, 52, 54, 78, 96, 97, 99, 101,  
 103–107, 143, 180, 191, 192,  
 194–201, 203, 221–222, 228, 259,  
 260  
 nanogels 38, 63–67, 72, 73, 119, 211, 279  
 nanomaterials  
 carbon nanomaterials 219–220  
 gold nanoparticles 215–217  
 lipid NPs (LNPs) 213–214  
 magnetic NPs 214–215

- nanomaterials (*contd.*)
- nanofibers 221–222
  - nanorods 225–226
  - nanowires 222–225
  - polymeric 211–212
  - quantum dots (QDs) 218–219
  - self-assembly of proteins and peptides 227–229
  - silica NPs 217–218
  - toxicity of 278–279
- nanomaterials technology 96
- nanomedicine 115, 116, 182, 209–211, 215, 277–279, 281
- nanoparticles (NPs)
- shape effect 140–141
  - size effect 138–139
  - surface charge 141–143
- nanorods 140, 141, 143, 216, 225–226
- nanotechnology 7, 8, 95, 96, 99, 109, 115, 116, 143, 144, 175, 182, 204, 209, 210, 223, 225, 228, 255, 273–277, 281
- nanotoxicology 116, 144, 210, 275
- nanotubes 99, 100, 123, 193, 203, 211, 219, 223, 228
- nanovaccinology 115, 209
- nanowires 99, 122, 140, 143, 222–225, 228
- natural polymers 12, 28, 29, 55, 68, 164, 214
- natural polysaccharide 29, 34, 38, 55, 222
- necrosis 116, 118, 120–121, 128, 139, 279, 280
- neovascularization 193, 195, 196
- nerve regeneration 69, 198–199, 221, 261, 262
- nonviral technologies 163
- NOVAFFECT Oligomeric chitosans 32
- nucleic acid-responsive hydrogels
- aptamer responsive-hydrogels 81–82
  - DNA-responsive hydrogels 80–81
  - PNA-responsive hydrogels 82
  - RNA-responsive hydrogels 80
- O**
- oxidative stress 116–118, 120–122, 129, 217, 274, 278
- P**
- pectins 29–31
- peptide amphiphile 75, 103, 106–108, 192, 195–199, 201, 203
- peptide amphiphile (PA) 50
- peptide nucleic acid (PNA) 48
- personalized medicine 11, 268
- pharmacokinetics (PK) 132, 136, 138, 141
- phenylboronic acid hydrogels 58–59
- photolithography 8, 28, 96, 177, 179, 181, 190, 191, 260–262
- PNA-responsive hydrogels 82, 84
- P(NIPAM-2-AAPBA) contraction-type microgels 64
- poly(acrylamide) (PAAm)-PBA hydrogels 62
- poly ( $\epsilon$ -caprolactone) (PCL) 24, 29, 258
- polycationic NPs 213
- poly-droxy ethyl methacrylate (PHEMA) sponges 262
- polyethersulfone (PES) 24
- poly(ethylene glycol) (PEG) 25, 27, 55, 57, 73
- polyglycolic acid (PGA) 29, 177, 190
- poly(glycolic acid) (PGA) 24, 258
- poly(L-lactic acid) (PLLA) 24
- polymer-encapsulated method 9
- polymeric micelles 211–213, 276, 281
- polymeric nanocarriers (PNC) 211
- polymeric scaffolds 176, 177, 189, 256, 259
- polymers, thermal properties 4
- protein constructs 211
- protein-responsive hydrogels
- antigen-responsive hydrogel 78–79
  - enzyme-responsive hydrogels 68
- proteins and peptides 7, 8, 95, 98–100, 109, 193, 203, 204, 218, 227–229
- pullulan 31, 35

**q**

quality assurance 272–273  
 quantum dots (Qds) 65, 211, 218–219,  
 274

**r**

regenerative medicine  
 definition 187  
 specific mediated biomaterials  
 191–193  
 tissue-engineered scaffolds 188–191  
 reversible/dynamic supramolecular  
 hydrogels 77  
 ribonucleic acid (RNA) 48, 211  
 RNA-responsive hydrogels 80, 84

**s**

scanning electron microscopy (SEM)  
 106, 123–124  
 schizophyllan 35  
 selenium-doped hydroxyapatite NPs  
 (Se-HNPs) 118  
 self-assembled systems  
 amphiphilic molecules 100  
 antimicrobial peptides 101–102  
 classification 98  
 drug delivery 104–108  
*in vitro* biological approaches 101  
 membrane proteins 108  
 proteins and peptides 98–99  
 regenerative medicine therapy 193  
 surfactant-like peptides 100  
 three-dimensional cell culture  
 102–104  
 three-dimensional peptides matrix  
 100–101  
 sensitive drugs 2  
 SFF scaffold manufacturing methods  
 177, 191, 261  
 silica NPs 211, 217–218  
 single-walled nanotubes (SWNTs)  
 219  
 siRNA delivery 32, 80, 166–167, 212  
 soft tissue regeneration 201–202  
 solvent casting 177, 190, 191, 260, 261

specific mediated biomaterials  
 angiogenesis 194–197  
 biomineralization 193–194  
 bone regeneration 197–198  
 cardiac regeneration 199–200  
 cartilage regeneration 193–194  
 nerve regeneration 198–199  
 self-assembled systems 193, 202–203  
 soft tissue regeneration 201–202  
 tooth regeneration 200–201  
 stimuli-responsive hydrogels 47, 48, 81  
 stress–cycle (S–N) curve 6  
 superparamagnetic iron oxide NPs  
 (SPIONs) 210  
 supramolecular hydrogels 60, 73–77,  
 105  
 synthetic polymer 5, 10, 24, 29, 122, 176,  
 211, 256, 258

**t**

target drug delivery 10, 84, 167–168  
 target therapy in cells 167–168  
 tensile test 5  
 tetrahedral DNA nanostructures (TDNs)  
 119  
 three-dimensional cell culture 102–104  
 3D culture technology 182  
 3D *in vitro* cell culture technology 263,  
 264  
 3D *in vitro* technology 183, 263  
 three-dimensional (3D) models 8, 175,  
 255  
 three-dimensional peptides matrix  
 100–101  
 3D scaffold fabrication 257  
 tissue engineered scaffolds 7, 95,  
 188–191, 198  
 tissue engineering 1, 7, 10, 11, 13, 23–25,  
 27–30, 47, 49, 68–72, 75, 80, 83, 84,  
 95, 99, 102, 103, 106, 109, 176, 177,  
 180, 182, 183, 187–194, 197–201,  
 204, 217, 220, 222, 225, 228, 255,  
 256, 258, 260, 263, 267, 274, 279  
 tooth regeneration 200–201  
 top-down approach 96

toxicity assessment of nanomaterials  
  *in silico* assay 130  
  *in vitro* cell-based cytotoxicity assay  
    127  
  *in vitro* characterization 123  
  *in vivo* studies 130  
  validity of *in vitro* assays 129–130  
transforming growth factor- $\beta$  (TGF- $\beta$ )  
  197  
transmission electron microscopy (TEM)  
  100, 124  
type-1 cell death 118

**U**

ultrasmall superparamagnetic iron oxide  
  nanoparticles (USPIOs) 215  
ultrasound technology 169–170  
upconverting NPs 210

**V**

validity of *in vitro* assays 129–130  
viral vectors 11, 32, 163–166

**W**

wear 5, 6

















